Research programme: hepatitis therapeutics - Assembly Biosciences
Latest Information Update: 11 Aug 2023
Price :
$50 *
At a glance
- Originator Assembly Biosciences
- Class Antivirals; Small molecules
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Hepatitis B; Hepatitis D
Most Recent Events
- 09 Aug 2023 Preclinical trials in Hepatitis B in USA (PO), prior to August 2023
- 09 Aug 2023 Preclinical trials in Hepatitis D in USA (PO), prior to August 2023
- 31 Mar 2023 Early research in Hepatitis D in USA (PO) (Assembly Biosciences pipeline, March 2023)